The global anti-obesity drugs market size surpassed USD 4.53 billion in 2023 and is estimated to increase from USD 5.69 billion in 2024 to approximately USD 55.25 billion by 2034. It is projected to grow at a CAGR of 5.53% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anti-Obesity Drugs Market
5.1. COVID-19 Landscape: Anti-Obesity Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anti-Obesity Drugs Market, By Type
8.1. Anti-Obesity Drugs Market Revenue and Volume, By Type, 2024-2034
8.1.1 Prescription Drug
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. OTC Drug
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Anti-Obesity Drugs Market, By Distribution Channel
9.1. Anti-Obesity Drugs Market Revenue and Volume, By Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Retail & Online Pharmacy
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Anti-Obesity Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Type (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By Distribution Channel (2021-2034)
Chapter 11. Company Profiles
11.1. Alvogen Iceland EHF
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Amgen Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca Plc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Boehringer Ingelheim International GmbH
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Eli Lilly and Co.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Empros Pharma AB
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. ERX Pharmaceuticals Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Gelesis Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. GlaxoSmithKline Plc
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Innovent Biologics Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample